Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 78 results
Filters: First Letter Of Title is P  [Clear All Filters]
Found 78 results.

2016

DiRienzo AGregory. "Parsimonious covariate selection with censored outcomes." Biometrics. 2016;72(2):452-62.
Freeman ML, Lederman MM, Gianella S. "Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection." Curr HIV/AIDS Rep. 2016;13(1):10-9.
Shivakoti R, Yang W-T, Berendes S, et al. "Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings." J. Infect. Dis.. 2016;213(7):1074-8.
Castillo-Mancilla JR, Aquilante CL, Wempe MF, et al. "Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)." J. Antimicrob. Chemother.. 2016;71(6):1609-18.
Verma SS, Frase AT, Verma A, et al. "PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG)." Pac Symp Biocomput. 2016;21:57-68.
Derache A, Wallis CL, Vardhanabhuti S, Bartlett J, Kumarasamy N, Katzenstein D. "Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection." J. Infect. Dis.. 2016;213(2):250-6.
Sinxadi PZuleika, McIlleron HMargaret, Dave JAlex, et al. "Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations." Medicine (Baltimore). 2016;95(2):e2385.
Makita-Chingombe F, Kutscher HL, DiTursi SL, Morse GD, Maponga CC. "Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations." J Drug Deliv. 2016;2016:3810175.
Hennig S, Svensson EM, Niebecker R, et al. "Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs." J. Antimicrob. Chemother.. 2016;71(5):1330-40.
Rutstein SE, Hosseinipour MC, Weinberger M, et al. "Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm." BMC Infect. Dis.. 2016;16(1):280.
Singini I, Campbell TB, Smeaton LM, et al. "Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy." HIV Clin Trials. 2016:1-8.
Shivakoti R, Christian P, Yang W-T, et al. "Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults." Clin Nutr. 2016;35(1):183-9.

2015

Gross R, Zheng L, La Rosa A, et al. "Partner-Focused Adherence Intervention for Second-line Antiretroviral Therapy: A Multinational Randomized Trial (ACTG A5234)." Lancet HIV. 2015;2(1):e12-e19.
Lee AJ, Bosch RJ, Evans SR, et al. "Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen." J. Neurovirol.. 2015;21(2):210-8.
Sha BE, Tierney C, Sun X, et al. "PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150." Jacobs J AIDS HIV. 2015;1(1).
Decloedt EH, van der Walt JS, McIlleron H, Wiesner L, Maartens G. "The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals." Int. J. Tuberc. Lung Dis.. 2015;19(10):1194-6.
Moore CB, Verma A, Pendergrass S, et al. "Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols." Open Forum Infect Dis. 2015;2(1):ofu113.
Vardhanabhuti S, Taiwo B, Kuritzkes DR, Eron JJ, Bosch RJ. "Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia." Antivir. Ther. (Lond.). 2015;20(1):73-6.
Balagopal A, Asmuth DM, Yang W-T, et al. "Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study." J. Acquir. Immune Defic. Syndr.. 2015;70(2):163-71.
Crump JA, Wu X, Kendall MA, et al. "Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study." BMC Infect. Dis.. 2015;15:12.
Orlov M, Smeaton LM, Kumwenda J, Hosseinipour MC, Campbell TB, Schooley RT. "Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population." PLoS ONE. 2015;10(6):e0129519.
Kantor R, Smeaton L, Vardhanabhuti S, et al. "Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial." Clin. Infect. Dis.. 2015;60(10):1541-9.
Stein JH, Ribaudo HJ, Hodis HN, et al. "A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness." AIDS. 2015;29(14):1775-83.

Pages